Re-test your knowledge
Re-test your knowledge
Summary
You have now completed Module 5 QUVIVIQ™ in practice. The cases of Bunmi and Steve exemplify two patient types who could benefit from QUVIVIQ™. QUVIVIQ™ can be prescribed second line (or later) after CBTi in patients with diagnosed chronic insomnia whose daytime functioning is being affected, or first‑line if CBTi is not available or not suitable.1,2 Attention should be paid to a patient’s comorbidities, for example, psychiatric conditions and compromised respiratory function including severe sleep apnoea, and where there is a history of substance abuse.1
Ready for the next module?
The impact of insomnia
QUVIVIQ™ is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to ds.safety.uk@idorsia.com
References
- QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics
- National Institute for Health and Care Excellence (NICE). Technology appraisal guidance 922. Daridorexant for treating long-term insomnia, 18 October 2023. Available at: nice.org.uk. Accessed August 2025
- Temazepam Summary of Product Characteristics
- Zolpidem Summary of Product Characteristics
- Zopiclone Summary of Product Characteristics
- Sleep Foundation. Aging and sleep, 19 September 2023. Available at: sleepfoundation.org. Accessed August 2025
- Miner B, Kryger M H. Sleep in the aging population. Sleep Med Clin 2017; 12(1): 31–38.
- Cohen Z L, Eigenberger P M et al. Insomnia and other sleep disorders in older adults. Psychiatr Clin North Am 2022;45(4):717-734
- Patel D, Steinberg J, Patel P. Insomnia in the elderly: a review. J Clin Sleep Med 2018;14(6):1017-1024
- National Institute for Health and Care Excellence (NICE). NICE guideline 202. Obstructive sleep apnoea/ hypopnoea syndrome and obesity hypoventilation syndrome in over 16s, 20 August 2021. Available at: nice.org.uk. Accessed August 2025
- National Institute for Health and Care Excellence (NICE). Clinical knowledge summary. Obstructive sleep apnoea syndrome. Scenario: management of sleep apnoea, November 2021. Available at: cks.nice.org.uk. Accessed August 2025
© NICE 2023 Daridorexant for treating long-term insomnia. Available from www.nice.org.uk/guidance/ta922. All rights reserved. Subject to Notice of rights.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/ publication.
UK-DA-00657 | Date of preparation: August 2025
